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Abstract: 
 Liver transplant recipients are vulnerable to infections with multidrug-resistant 
pathogens.  Risk factors for colonization and infection with resistant bacteria are ubiquitous 
and unavoidable in transplantation.  During the past decade, progress in transplantation and 
infection prevention has contributed to the decreased incidence of infections with methicillin-
resistant Staphylococcus aureus.  However, even in the face of potentially effective antibiotics, 
vancomycin-resistant enterococci continue to plague liver transplantation. Gram-negative 
bacilli prove to be more problematic and are responsible for high rates of both morbidity and 
mortality.   Despite the licensure of novel antibiotics, there is no universal agent available to 
safely and effectively treat infections with multidrug-resistant Gram-negative organisms.  
Currently, efforts dedicated toward prevention and treatment require involvement of multiple 
disciplines including transplant providers, specialists in infectious diseases and infection 
prevention, and researchers dedicated to the development of rapid diagnostics and safe and 
effective antibiotics with novel mechanisms of action. 
 
Introduction 
Even with great improvements in infection prevention, surgical technique, and 
immunosuppression; bacterial infections remain responsible for poor outcomes in liver 
transplantation.   In an era of prolonged wait times, repeated and unavoidable exposures to 
both healthcare and antibiotics place liver transplant (LT) candidates and recipients at high risk 
for both colonization and infection with multidrug-resistant organisms (MDROs). Multidrug 
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resistance is frequently defined as bacteria resistant to at least one agent in at least three 
different antibiotic classes(1).  Despite this accepted definition, the definitions applied in 
studies describing MDROs are variable.  MDRO colonization has been associated with 
subsequent infection and surgical complexities, requirement for immunosuppressive therapy, 
and necessary invasive interventions (e.g., central venous catheters, urinary catheters, and 
mechanical ventilation) also add to the risk of MDRO infection in this susceptible population. In 
the absence of post-transplant complications, bacterial infections are more common early post-
LT(2).   Rarely donor transmission of a MDRO has been reported.   
Delays in effective empirical therapy, lack of experience with older and newer agents, 
and ever-changing susceptibility profiles in the setting of inadequate source control or selective 
antibiotic pressures contribute to the difficulties in treating patients infected with MDROs, 
specifically MDR Gram-negative bacilli.   In this review, we highlight risk factors and available 
treatment for some of the more common and problematic MDROs encountered in liver 
transplantation.  
 
Multidrug-resistant Gram-positive cocci 
 Historically, infections with Gram-positive organisms, specifically Staphylococcus aureus   
and enterococci, were a common source of complications post-LT.  Public awareness of the 
impact of methicillin-resistant Staphylococcus aureus (MRSA) likely has contributed to advances 
in both prevention and treatment of staphylococcal infections(3).    Unfortunately, infections 
with enterococci continue to be common among LT recipients.  Vancomycin-resistant 
enterococci (VRE), although less virulent, can confound an already problematic post-LT course 
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especially in the setting of surgical complications and prolonged hospital stays.   The advent of 
both linezolid and daptomycin has changed the overall landscape of enterococcal infections, 
however, resistance has been described and novel therapeutics remain unproven(4-8). 
 
Methicillin-resistant Staphylococcus aureus (MRSA) 
Overall rates of invasive MRSA are declining(9).  The precipitous drop in MRSA infections 
coincide with increased emphasis on infection prevention practices including rigorous 
adherence to hand hygiene and isolation precautions, perioperative skin antisepsis, central 
venous catheter insertion and maintenance bundles, active surveillance with or without 
decolonization, and universal daily bathing with chlorhexidine gluconate in select settings like 
intensive care units (ICUs)(10). 
Most studies exploring the risk factors, prevalence, and incidence of MRSA in liver 
transplantation are single center evaluations from the United States in the setting of active 
surveillance(11).  MRSA infection reportedly occurs in 4-23% of LT recipients(12) though more 
contemporary studies suggest lower rates(13). Colonization with MRSA, specifically nasal 
carriage, is a significant risk factor for subsequent MRSA infection post-LT(14, 15).  A recent 
meta-analysis estimated the prevalence of MRSA colonization pre-LT to be nearly 12% with 
similar rates (13%) post-LT.  In this study pre- and post-LT MRSA carriage was associated with 
close to a 6-fold and 11-fold respective increase in MRSA infection(11).  
Other cited risk factors for MRSA infection have been summarized elsewhere(16) but 
include prolonged hospitalization, broad-spectrum antibiotic use, primary cytomegalovirus 
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infection, extended ICU stay, and peritonitis.   Donor-derived MRSA infections have been 
described(17-19).   
Isolated MRSA colonization has not been directly associated with mortality(11, 15).   The 
association between MRSA infection and mortality in liver transplantation is evolving.   More 
recent studies do not demonstrate an increased risk of mortality(12, 14, 15). 
While rare in LT recipients, vancomycin-intermediate S. aureus (VISA) and 
heteroresistant VISA (hVISA) can potentially complicate treatment of MRSA.  Description of a 
French cohort implies increased prevalence (13/48, 27%) of hVISA was the result of clonal 
transmission(16). Vancomycin-resistant S. aureus (VRSA) has not yet been reported in liver 
transplantation.  Nevertheless, vancomycin resistance is a viable concern given the potential for 
transfer of enterococcal vanA elements to S. aureus(20) and the prevalence of VRE in the LT 
population.  
Vancomycin arguably remains the mainstay for treatment of MRSA(21) and the 
treatment of MRSA infections in transplantation has been reviewed in detail(16).  Commonly 
used licensed alternatives to vancomycin include linezolid and daptomycin.  Data exist 
suggesting increased rates of clinical failure with vancomycin in the setting of higher 
vancomycin minimum inhibitory concentrations (> 1.0 mg/L)(22).   Evidence suggests the non-
inferiority of daptomycin in the treatment of MRSA bacteremias(23).   Retrospective studies 
suggest daptomycin may portend better outcomes in the setting of bacteremias when MIC > 1 
mg/L (24, 25).   However, prospective trials assessing the superiority of daptomycin over 
vancomycin in the setting of elevated MICs are in their infancy.  A recent multicenter evaluation 
Page 5 of 35
John Wiley & Sons, Inc.
Liver Transplantation
This article is protected by copyright. All rights reserved.
suggested no difference in composite failures between vancomycin and daptomycin, but higher 
rates of nephrotoxicity in patients receiving vancomycin(26).  
Of increasing concern is resistance to both daptomycin and linezolid is being reported.  
What is increasingly alarming is that resistance is being described in the absence of drug 
exposure(27).     
Recently, several agents with potential activity against MRSA have been licensed 
primarily for the treatment of skin and soft tissue infections.  They include the 
lipoglycopeptides, oritavancin, telavancin, and dalbavancin; ceftaroline, an antistaphylococcal 
cephalosporin; and tedezolid, a new oxazolidinone.   Although in vitro data exist suggesting 
activity against MRSA, clinical data in transplant recipients are scarce.   
Though a single center’s experience demonstrated a decrease in both S. aureus infection 
and colonization in LT patients with targeted active surveillance, decolonization, and infection 
prevention measures(28) recommendations and randomized trials regarding timing, frequency 
and specific decolonization regimens are limited(11).  In the setting of deceased donor 
transplantation, timing and durability of decolonization remain unclear. 
 
Vancomycin-resistant enterococci (VRE) 
Unlike MRSA, acquisition of VRE remains associated primarily with exposure to 
healthcare.  Antibiotic use, length of hospitalization, and environmental contamination are 
associated with VRE acquisition.  Similar to MRSA, colonization frequently precedes 
infection(11).   A recent meta-analysis, inclusive of studies from the US and Brazil, estimated 
the prevalence of pre- and post-LT VRE colonization to be 12% and 16% respectively.   If this 
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study was exclusive to the US, the prevalence of colonization was 16% pre- and 22% post-LT.  
Pre-LT VRE colonization was associated with a nearly 7-fold increase in VRE infection, with an 
additional 8-fold increase post-transplantation(11).    
Biliary complications (e.g., leaks and strictures) with subsequent re-explorations and 
interventions predispose LT recipients to VRE(20, 29, 30).  Prior to the advent of quinopristin-
dalfopristin and linezolid, VRE-associated morality rates ranged between 33 to 82% in LT 
patients(31).  Acquisition post-transplantation was associated with the highest mortality 
risk(15, 29).  
 Treatment of VRE in organ transplantation has been extensively reviewed(4) and the 
two most commonly used antibiotics, daptomycin and linezolid, are safe and well-tolerated in 
this population(32, 33).    Linezolid-resistant VRE has been described in LT recipients in the 
setting of linezolid exposure as well as horizontal transmission(34, 35).  Daptomycin-
nonsusceptible enterococci have been recovered in liver transplant recipients with and without 
prior exposure to daptomycin(5, 36).    
Other agents with potential activity against VRE include telavancin and ceftaroline.  
Neither demonstrates reliable activity against E. faecium although televancin may have activity 
against vanB strains.  Oritavancin demonstrates in vitro activity against vanA and vanB 
harboring strains of enterococci, however, clinical data for its use in severe infections are 
lacking.  Tedezolid has demonstrated in vitro activity against linezolid, daptomycin, and 
vancomycin-resistant staphylococci and enterococci(6).  Increasing in vitro and case-specific 
data are emerging regarding combination therapy for the treatment of VRE(7, 8).  No specific 
combination has been studied in clinical trials. 
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Outside of outbreaks or hyperendemicity, there is no established role for active VRE 
surveillance in LT candidates or recipients(20).  However, known colonization may allow for 
alteration of perioperative regimens to include anti-VRE therapy(37).  Contact precautions 
should be implemented when asymptomatic colonization is established(20) to prevent 
horizontal transmission especially in high-risk settings like transplantation units or ICUs.   
 
Resistant Gram-negative bacilli 
 During the last 15 years, a shift in the microbiology of post-LT infections has occurred 
with a marked increase in Gram-negative infections(38).  Accounts of multidrug-resistant Gram-
negative pathogens in LT recipients are growing with centers worldwide reporting rates of 
>50%(39, 40).  Risk Factors for MDR Gram-negative infections post-LT include re-exploration, 
abdominal infections, and acute allograft rejection(39).  Infection with resistant isolates is 
associated with significantly increased mortality rates(39-42).   
 
Extended Spectrum Beta-Lactamase (ESBL) producing Enterobacteriaceae 
The production of β-lactamases, enzymes able to hydrolyze β-lactam antibiotics, is a 
common cause of resistance among Enterobacteriaceae, including Escherichia coli and 
Klebsiella pneumoniae.   Extended-spectrum β-lactamase (ESBL) producing Enterobacteriacae 
are genetically diverse and have been recovered in both the community and healthcare 
settings.  It is not surprising that in a population with universal exposure to antibiotics and 
healthcare, these pathogens are frequently recovered in LT candidates and recipients.  
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Rates of ESBL infection vary from 5.5-12.8% in non-endemic areas(43).  In endemic 
areas, rates can be considerably higher and mortality in the setting of infection has been 
reported to be as high as 40% despite appropriate antibiotics(44).  Independent predictors of 
gastrointestinal carriage of ESBLs in LT candidates include recent history of spontaneous 
bacterial peritonitis and recent receipt of a β-lactam antibiotic(44).   In addition to pre-LT 
colonization, advanced liver disease and repeated explorations are cited risk factors for 
subsequent infection with ESBL-producing organisms.  
Concomitant carriage of multiple resistance determinants confounds the treatment of 
infections with ESBL-producing Enterobacteriaceae.  Carbapenems remain the drugs of choice.  
Despite in vitro susceptibilities, piperacillin-tazobactam and cefepime are not reliable in severe 
infections but may be used with less severe infections where the agent concentrates well like 
urinary tract infections.    
Similar to MRSA and VRE, the Centers for Disease Control and Prevention (CDC) 
recommends contact isolation be routinely used for all ESBL-producing Enterobacteriaceae 
irrespective of species(45). Controversy exists regarding the need for these precautions for 
patients colonized or infected with ESBL-producing E. coli as horizontal transmission appears to 
be low as compared to to ESBL-producing K. pneumoniae(46, 47) The practicality of excluding 
ESBL-producing E. coli from isolation protocols may be challenging especially in high risk 
settings like liver transplantation.  
 
Carbapenem-resistant Enterobacteriaceae (CRE) 
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Carbapenem-resistant Enterobacteriaceae (CRE), particularly carbapenem-resistant K. 
pneumoniae (CRKP), have been increasingly described among organ transplant recipients in the 
past decade(48).    Carbapenem resistance can be conferred by a variety of resistance 
mechanisms; however, expression of carbapenemases is most common.  In the US, expression 
of K. pneumoniae  carbapenemases (KPCs) is the most frequently observed mechanism of 
resistance.  However, recovery of metallo-β-lactamases (MBL)(49) and carbapenem-hydrolyzing 
class D carbapenemases (oxacillinase-48 (OXA-48)) has been described(50).  CRE often is 
multidrug-resistant and no available agent (Table 1) demonstrates universal activity, thus 
further complicating treatment.  
Reported rates of CRKP in LT recipients range from 6 – 12.9%(51, 52) accounting for 23% 
of all bacterial infections post-LT in one center in New York(53). In LT recipients, reported 
associated mortality ranges from 18% to nearly 80%(51, 53-55).   Non-transplant specific risk 
determinants for acquisition and infection with CRKP include exposure to broad-spectrum 
antibiotics, high prevalence of CRKP, and severity of illness (e.g., need for invasive devices or 
ICU stay)(56).  These risk factors are intrinsic to transplantation, especially liver transplantation.  
Most published studies evaluating the risk and impact of CRKP in LT are single center and in the 
setting of incomplete assessment of colonization status.   
Contemporary studies of large cohorts of LT patients with CRKP cite advanced liver 
disease, hepatocellular carcinoma, Roux-en-Y anastomosis, post-operative biliary leaks, renal 
replacement therapy, prolonged ventilator support, and recurrence of hepatitis C virus 
infection as significant predictors of subsequent CRKP infection(51, 54).  When the information 
is available, pre-LT colonization appears to be a risk factor for post-LT CRKP infection(54, 55).  In 
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an Italian cohort, 4.6% of pre-LT patients were colonized with CRKP(54).  Those LT recipients 
colonized prior to LT were at higher risk of LT infection than those not colonized.  Those LT 
recipients with colonization detected after transplantation appeared to have the highest attack 
rates(54).  
The treatment of CRE is exceedingly complex and has recently been reviewed(57).    
Although none provide universal activity against CRE, available agents with potential activity 
against these pathogens include aminoglycosides, polymyxins (colistin and polymyxin B), and 
tigecycline.  In the setting of cystitis, fluoroquinolones, fosfomycin and nitrofurantoin can 
potentially be used.    
Much debate surrounds the use of polymyxins: drug (colistin versus polymyxin B), dose, 
and the emergence of resistance on therapy(57).   In addition to source control(58), many 
experts recommend the use of combination therapy, with or without carbapenems, to treat 
CRE(48, 59, 60).  The success of specific combinations may rely on the underlying resistance 
mechanisms highlighting the role of rapid diagnostics(60).  Trials systematically evaluating the 
role of polymyxin-based combination therapy are in progress.   
The recent licensure of ceftazidime-avibactam adds to the arsenal of antibiotics 
available to treat CRE.  In vitro activity depends on the specific carbapenemase being expressed 
with no reliable activity against MBLs (e.g., New Delhi MBL (NDM)).   Resistance among KPC-
producing K. pneumoniae has been recently reported(61).  Plazomicin (ACHN-490), an 
investigational aminoglycoside, demonstrates potent in vitro activity against CRE including 
those producing MBLs.  Intravenous fosfomycin has been used to treat systemic infections 
outside of the US(42, 57). 
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Potential eradication of CRKP gastrointestinal colonization using oral gentamicin and 
oral polymixin E (colistin) has been evaluated with some success(62).   However, subsequent 
analyses of breakthrough post-treatment isolates reveal significant increases in rates of colistin 
and gentamicin resistance(63).  Donor transmission of CRE has been reported(64, 65).  
Colonization or infection with CRE is not an absolute contraindication to liver 
transplantation.  High associated mortality rates should prompt providers to take pause and 
weigh this risk as they would other comorbid conditions prior to proceeding with 
transplantation. 
 
Multidrug-resistant Pseudomonas aeruginosa 
Pseudomonas aeruginosa has the unique ability to harbor and accrue numerous 
resistance determinants(66) making multidrug resistance frequent.   Recovery of MDR P. 
aeruginosa is not uncommon in organ transplantation(48).  P. aeruginosa recovered from organ 
transplant recipients demonstrates higher rates of carbapenem resistance compared to isolates 
from non-transplant recipients(67).   Reports in LT recipients are often in the setting of single 
center outbreaks or high local prevalence(68, 69).   Rates of P. aeruginosa bloodstream 
infections in LT range from 6.5-10%(48), with over 50% of isolates demonstrating multiple drug 
resistance(39).  
Although recommended by many experts, the role of routine combination therapy for 
the treatment of P. aeruginosa infections remains controversial(70).   Many may want to 
consider combination therapy up front while awaiting susceptibilities especially in the setting of 
unpredictable resistance patterns.  Both ceftazidime-avibactam and ceftolozane-tazobactam do 
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demonstrate activity versus select strains(57).    Neither novel cephalosporin/β-lacatamase 
inhibitor combination inhibits MBLs.  Plazomicin potentially has in vitro activity against some 
isolates of P. aeruginosa.  However, like with CRE, the mechanism of underlying aminoglycoside 
resistance influences activity. 
 
Carbapenem-resistant Acinetobacter baumannii (CRAB) 
 Similar to multidrug resistance among P. aeruginosa, the definition of multidrug 
resistance(1) varies across publications describing local experiences with Acinetobacter 
baumannii in organ transplantation.   Most reports evaluating risks and outcomes associated 
with acquisition carbapenem-resistant Acinetobacter baumannii (CRAB) reflect the experience 
of single centers and are not exclusive to LT(71).   CRAB has been reported in LT recipients with 
resistance rates of up to 95%(72, 73)Healthcare-associated pneumonia, including ventilator-
associated pneumonia, is the most commonly reported presentation of CRAB infection in LT 
recipients.  In some centers, up to 24% of bloodstream infections in LT recipients were caused 
by A. baumanii with multidrug resistance found in >50% of isolates(39, 74, 75)  Like the other 
MDROs described, organ transplant recipients colonized with CRAB may subsequently develop 
infection(76).  In-hospital mortality related to Acinetobacter infections can be unacceptably 
high in LT(74) with  associated mortality rates of over 50%(76, 77)and up to 90% in the ICU(78).    
Treatment of MDR A. baumannii remains difficult.  Studies from a single medical center 
in the US suggest that combination therapy with colistin and a carbapenem portend better 
survival rates among organ transplant recipients(76).   However, the emergence of colistin 
resistance is not uncommon(73, 76). 
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In addition to polymxins, aminoglycosides, minocycline, and tigecycline have been used 
to treat CRAB infections with varying degrees of success.  Sulbactam, a β-lactamase inhibitor, 
demonstrates intrinsic activity against A. baumannii.  In many centers, ampicillin-sulbactam 
demonstrates the best activity against CRAB(42) and based on local susceptibility patterns may 
be the most appropriate empirical choice for the treatment of suspected A. baumannii 
infection.  In terms of newer agents, neither ceftazidime-avibactam nor ceftolozane-
tazobactam demonstrates reliable activity against A. baumannii.  Depending on the mechanism 
of aminoglycoside resistance, plazomicin may have activity against specific isolates particularly 
in combination with carbapenems(79). 
 
Conclusion 
Most bacterial infections occur early after transplantation in the setting of 
hospitalization and intensive care.  Infection prevention and antibiotic stewardship(80) remain 
paramount in mitigating the emergence and transmission of MDROs.   In addition to strict 
adherence to hand hygiene, isolation precautions, and environmental disinfection 
recommendations; patient-specific bundles have been shown to decrease device-associated 
infections and surgical site infections(81).    Avoiding these healthcare-associated infections 
may be the “easy pickings” in liver transplantation. 
In terms of device-associated infections, daily assessment of continuing need for devices 
(e.g., central venous catheters and urinary catheters) and prompt removal when no longer 
necessary may offer substantial benefits to the post-transplant patient by decreasing the 
infection risk and allowing early patient mobilization(81).  Universal bathing with chlorhexidine 
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gluconate to reduce MDRO acquisition remains debatable(82, 83) and has been untested in 
liver transplantation specifically.  Although active surveillance has been used in liver transplant 
to identify patients requiring isolation and at-risk patients(37), the use of active surveillance 
outside of an outbreak setting cannot be categorically recommended.    
 Diagnosing and treating infections in liver transplantation can be challenging(2).  Early 
and appropriate antibiotics in the setting of severe bacterial infections are associated with 
better patient outcomes(84) (Figure 1).  Consequently, broad-spectrum antibiotics are 
frequently used as first-line in the setting of suspected infection irrespective of severity.  This 
empiric approach to antibiotics may lead to overuse and prolonged use as optimal treatment 
regimens and durations for infectious syndromes in organ transplant recipients are not 
specifically defined(85).   Antimicrobial stewardship programs (ASP) have been shown to 
decrease both antimicrobial overuse and prevalence of MDROs as well as improve clinical 
outcomes (86).  Unfortunately, studies evaluating ASP in organ transplantation are limited (85, 
87, 88) and the extrapolation of therapeutic plans from existing non-transplant specific 
guidelines can be divisive.   A recent audit of a large Canadian transplant network found 
significant opportunities for ASP in organ transplantation(88).  With the disproportionate 
presence of MDROs in liver transplant, these patients stand to significantly benefit from 
prudent antibiotic use.    Implementation of rapid diagnostics (e.g., Matrix-assisted laser 
desorption/ionization (MALDI) or multiplex polymerase chain reaction (PCR) platforms)  may 
allow for early identification of pathogens allowing for earlier broadening, discontinuation, and 
de-escalation of empiric regimens.  Novel antibiotics targeting MDROs, specifically Gram-
negative bacilli, are limited (Table 1) and studies evaluating optimal therapeutic management 
Page 15 of 35
John Wiley & Sons, Inc.
Liver Transplantation
This article is protected by copyright. All rights reserved.
are lacking.   Thus, in order to preserve available antibiotics and decrease the risk for increased 
resistance and for Clostridium difficile infections, the length of prescribed therapy should based 
on culture data and patient response rather than arbitrary based on physician comfort.   Studies 
inclusive of liver transplant patients have demonstrated that each day of antibiotic exposure 
increases likelihood of MDRO acquisition(56).    
 Finally, in the setting of a dearth of antibiotics, knowledge of local epidemiology should 
influence empirical antimicrobial decision-making.  Irrespective of the acuity of disease, LT 
patients are likely to become colonized and/or infected with the MDRO that is most frequently 
isolated in the units to which they are most commonly admitted.  A pathogen common at one 
center may not be common at another center and susceptibility profiles vary drastically.   
Empiric broad-spectrum therapy, including multiple agents directed toward multidrug-resistant 
Gram-negative bacilli in a severely ill patients may be appropriate, however prolonged therapy  
in the absence of culture data is not.  A multidisciplinary approach, including hepatologists, 
surgeons, intensivists, infectious diseases physicians, pharmacists, and microbiologists, is 
mandatory in order to improve the care of this growing population of patients and prevent 
continuing recovery of relatively untreatable pathogens. 
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Abbreviations: 
 
ASP  Antibiotic stewardship program 
CDC  Centers for Disease Control and Prevention 
CRAB  carbapenem-resistant Acinetobacter baumannii 
CRE  carbapenem-resistant Enterobacteriaceae 
CRKP  carbapenem-resistant Klebsiella pneumonia 
ESBL  extended-spectrum β-lactamase 
hVISA  heteroresistant vancomycin-intermediate Staphylococcus aureus 
ICU  intensive care unit 
LT  liver transplant 
KPC  Klebisella pneumoniae carbapenemases 
MBL  metallo-β-lactamase 
MIC  minimum inhibitory concentration 
MDR  multidrug-resistant 
MDRO  multidrug-resistant organism 
MRSA  methicillin-resistant Staphylcoccus aureus 
NDM  New Delhi metallo-β-lactamase 
OXA  oxacillinase 
US   United States 
VISA  vancomycin-intermediate Staphylcoccus aureus 
VRE  vancomycin-resistant enterococcus 
VRSA  vancomycin-resistant Staphylococcus aureus 
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Table 1:  Antibiotics commercially available or in advanced clinical trials with activity against carbapenem-resistant Gram-negative 
bacilli*(57, 89, 90) 
 Carbapenem-resistant 
Enterobacteriaceae 
 
 
 
 
Carbapenem-
resistant 
Pseudomonas 
aeruginosa† 
Carbapenem-
resistant 
Acinetobacter 
baumannii 
Special considerations 
and comments 
 KPC MBL (e.g., 
NDM) 
OXA-48    
Commercially available antibiotics 
Aminoglycosides 
(e.g., gentamicin, 
tobramycin, amikacin) 
X X X X X • Associated with 
nephrotoxicity and 
ototoxicity. 
• Therapeutic drug 
monitoring 
recommended to 
achieve optimal 
bacterial killing 
and decrease 
toxicity. 
Ceftazidime-avibactam X  X X   
Ceftolazone-tazobactam    X   
Fosfomycin X X X   • Parenteral 
formulation not 
available in the US. 
• Often used in 
combination with 
other agents 
except for simple 
cystitis. 
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Polymyxins (e.g., colistin 
and polymyxin B) 
 
X 
 
X 
 
X 
 
X 
 
X 
• Studies suggesting 
combination 
therapy may 
portend better 
outcomes than 
monotherapy. 
• Associated with 
nephrotoxicity and 
neurotoxicity. 
Tigecycline X X X  Minimal • Associated with 
increased 
mortality.  Not 
recommended for 
primary 
bloodstream 
infections due to 
rapid 
concentration into 
tissues.   
• Poor penetration 
into urine. 
Agents in advanced stages of development 
Ceftaroline/avibactam  X  X   Phase II, anti-MRSA 
cephalosporin/ β -
lactamase inhibitor 
Eravacycline X X   X Phase III, fluorocycline 
Imipenem/relebactam X   X†   Phase III, carbapenem/ 
β -lactamase inhibitor 
Meropenem/vaborbactam X     Phase III, 
carbapenem/boronic 
acid β - lactamase 
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inhibitor 
Plazomicin X  X X†  Phase III, 
aminoglycoside 
 
KPC- Klebsiella pneumoniae carbapenemase, MBL- metallo-β-lactamase, OXA- oxacillinase, MRSA- methicillin-resistant 
Staphylococcus aureus 
* Susceptibilities vary depending on concomitant resistance mechanisms 
† Dependent upon mechanism of resistance 
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 Send appropriate cultures including blood 
cultures and image as appropriate.  Early post-
transplantation, healthcare-associated 
infections including surgical site infections are 
common. 
 
Empiric Antibiotics 
• Drug should be appropriate for suspected 
source and local susceptibility patterns. 
• Dose should be appropriate for patient’s body 
habitus and creatinine clearance.  
• In the setting of concern for MRSA consider 
empiric vancomycin 15 mg/kg 
• In the setting of multidrug-resistant Gram-
negative pathogens consider adding a second 
agent (e.g., aminoglycoside or polymyxins) 
until susceptibilities are available especially in 
the setting of severe sepsis or shock.  The 
choice should be based on commonly isolated 
pathogens and local antibiograms. 
Suspected Bacterial Infection 
 
 
Cultures negative after 48 
hours 
Cultures positive  
• Narrow antibiotic regimen based 
on antibiotic susceptibilities. 
• Discontinue agents added 
empirically that are duplicative in 
spectrum or cover organisms not 
detected in cultures. 
• Convert parenteral agents to oral 
if amenable based on patient’s 
oral intake and drug 
bioavailability. 
• Discontinue* therapy based on 
patient’s clinical improvement 
rather than arbitrarily prescribing 
a course. 
*Minimal data on duration exists in LTR and antibiotic prescribing should be based on individual 
patient characteristics (immunosuppression, source control, response etc.) 
• De-escalate or discontinue 
antibiotics (discontinue 
broad-spectrum agents if 
cultures unrevealing). 
 
Source Control 
• Remove central venous catheters and 
urinary catheters as appropriate 
• Drain abscesses and collections if 
amenable 
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